MCK Q2 Beat Affirms Specialty Strength, but Valuation Leaves Little Room

What happened

McKesson reported fiscal Q2 2027 earnings that beat estimates, driven by strong specialty growth and higher prescription volumes, and management raised full-year guidance. The results confirm the oncology and specialty strategy is delivering, with the Oncology & Multispecialty segment posting 32% revenue growth and 71% adjusted operating profit growth. However, the market's muted after-hours reaction and the stock's elevated valuation suggest expectations are already high. The company's growth is partly acquisition-aided, and legal risks from opioid litigation remain. The report does not change the view that risk-reward is skewed toward trimming rather than adding.

Implication

Investors should view the guidance raise as consistent with the existing thesis but not a reason to chase the stock. With the shares near the upper end of our valuation range, the margin of safety is thin. We would use strength to trim positions and wait for a pullback closer to $720 before adding. The key remains whether organic growth in oncology can sustain without acquisition benefits and whether opioid litigation stays manageable. If those uncertainties resolve favorably, the stock could re-rate higher, but current prices do not compensate for the risks.

Thesis delta

The Q2 beat and raised guidance affirm the specialty growth narrative, but they do not alter our cautious stance. The results highlight the reliance on acquisitions and one-time gains, and the legal overhang remains. We maintain our POTENTIAL SELL rating with a trim above $880 and attractive entry at $720. The earnings beat does not change the risk-reward profile at current levels.